TORONTO, April 21 /CNW/ - Biosign Technologies Inc. (TSX-V: BIO; "Biosign"), issues the following statement as a result of unusual stock activity
in trading of the company's common shares:
Other than a news release issued by Biosign on April 19, 2011,
announcing the departures of a director and the Chief Executive
Officer, the company is not aware of any corporate developments outside
of the ordinary course of business that might explain the stock
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
| Radu Leca, President & CEO |
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
| || || || || || Alan S. Roemer, SVP |
The Trout Group LLC
Phone: 646 378-2945